ADMA Biologics, Inc.ADMANASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank93
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Percentile
P93
Near historical high
vs 2Y Ago
7.3x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$27.82M-74.7%
2024$110.10M+2782.9%
2023$3.82M+105.2%
2022$-73.42M+41.7%
2021$-125.88M-9.7%
2020$-114.73M-43.4%
2019$-80.01M-23.5%
2018$-64.77M-62.1%
2017$-39.95M-117.8%
2016$-18.34M-